Atrial fibrillation, venous thrombo-embolism, heart valve repair Boezemfibrilleren, trombose, longembolie, hartklepvervanging
Conditions
Interventions
One group is dosed using tablets of 0.5 milligrams of acenocoumarol, while the other group uses the regular 1.0 milligram tablets. Both will be dose-adjusted to their previously determined INR target
Sponsors
University Medical Center Groningen
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Using acenocoumarol for any indication, and being managed by Certe Trombosedienst - 80 years of age or older at time of inclusion - Using acenocoumarol with an average daily dose of less than 2 milligrams in the previous three months - Subject provided informed consent
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Initiated therapy with acenocoumarol in the last nine months - Expected termination of VKA within six months - Dosing step lower than or equal to "step 7", i.e. usage of less than 3.5 milligrams acenocoumarol per week. Patients who use such a low dose generally have an unfavourable prognosis. - Patients who determine the acenocoumarol dose themselves
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is quality of anticoagulation (individual time in therapeutic range and INR variability). | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary study parameters are treatment satisfaction, medication errors and number of INR measurements. | — |
Contacts
Public ContactJasper (J.H.A.) van Miert
UMCG
Outcome results
None listed